CLINICAL TRIAL: CHILDHOOD ABSENCE EPILEPSY: RX, PK-PD-PHARMACOGENETICS

临床试验：儿童失神癫痫：RX、PK-PD-药物遗传学

• 批准号: 8166799
• 负责人: DORIS A TRAUNER
• 金额: $ 0.24万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166799
• 关键词: Absence Epilepsy; Anticonvulsants; Child; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Incidence; Institution; Pharmacogenetics; Research; Research Personnel; Resources; Seizures; Source; Toxic effect; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To identify the optimal anticonvulsant (i.e. the AED with the highest rate of seizure control and lowest incidence of treatment limiting toxicity) used for the initial treatment of children with Childhood Absence Epilepsy (CAE).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 为了确定最佳抗惊厥药（即，癫痫发作控制率最高的AED和治疗限制毒性的最低发生率）用于初始治疗儿童缺勤癫痫（CAE）的儿童。